Gedeon Richter Provides Clues On Key Biosimilar Trial Dates

Denosumab And Tocilizumab In Richter’s Pipeline

 
• By Dean Rudge

Hungary’s Gedeon Richter achieved record results in 2020, driven by a near trebling of the firm’s group operating profit and rising sales. Management once again had much to say on the company’s biosimilar ambitions.

Open doors
Richter will continue to grow R&D spending in 2021, given that CNS and in biosimilars projects are entering into the clinical phase • Source: Shutterstock

More from Biosimilars

More from Products